Mastering the FDA Drug Approval Process: Strategies for Success in the US Pharmaceutical Market (February 6-7, 2024)
02 nov. 2023 07h28 HE
|
Research and Markets
Dublin, Nov. 02, 2023 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" conference has been added to ResearchAndMarkets.com's offering. The US...
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma
03 oct. 2023 08h30 HE
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma Biodexa Pharmaceuticals PLC, (Nasdaq:...
Interim results for the six months ended 30 June 2023
29 sept. 2023 16h30 HE
|
Biodexa Pharmaceuticals PLC
29 September 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended 30 June 2023 Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage...
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)
21 sept. 2023 08h30 HE
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at...
Global Orphan Drugs Market Research Report 2023
19 sept. 2023 05h38 HE
|
Research and Markets
Dublin, Sept. 19, 2023 (GLOBE NEWSWIRE) -- The "Orphan Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global orphan drugs market is expected to grow...
Infant Bacterial Therapeutics AB (publ), Delårsrapport 1 januari – 30 juni 2023
25 août 2023 02h30 HE
|
Infant Bacterial Therapeutics AB
VD Kommentarer Vår Fas III-studie, den största studien av sitt slag som någonsin genomförts, fortskrider på 88 sjukhus och i tio länder. Vi har nu rekryterat 85% av patienterna (1824 av de...
Infant Bacterial Therapeutics AB (publ) Interim report January 1 - June 30, 2023
25 août 2023 02h30 HE
|
Infant Bacterial Therapeutics AB
Message from the CEO Our Phase-III study, the largest of its kind ever conducted, is progressing across 88 hospitals in ten countries. We have now recruited 85% of the patients (1824 out of the...
Orphan Drugs and Rare Diseases Conference: Life-saving Therapies, Critical Issues, and Strategies to Enhance Orphan Drug Development in near future (London, United Kingdom - October 9-10, 2023)
14 août 2023 04h13 HE
|
Research and Markets
Dublin, Aug. 14, 2023 (GLOBE NEWSWIRE) -- The "Orphan Drugs and Rare Diseases Conference" conference has been added to ResearchAndMarkets.com's offering. The 4th Annual Orphan Drugs and Rare...
Over 1000 Orphan Drugs in Clinical Trials in the US - Eylea, Actimmune, Ravicti Among Key Approved Therapies
07 août 2023 06h43 HE
|
Research and Markets
Dublin, Aug. 07, 2023 (GLOBE NEWSWIRE) -- The "US Orphan Drugs Market, Drugs Sales, Price, Dosage & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. ...
Avexitide: A 31-amino Acid Peptide that Selectively Targets and Blocks GLP-1 Receptors - Emerging Drug Insights and Market Forecasts, 2019-2022 & 2023-2032
01 août 2023 06h28 HE
|
Research and Markets
Dublin, Aug. 01, 2023 (GLOBE NEWSWIRE) -- The "Avexitide Emerging Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering. "Avexitide Emerging...